Germany - Drugs
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 31 January 2025
- Opportunity publication date
- 27 December 2022
- Category
- 33600000
- Value of contract
- to be confirmed
- Your guide to exporting
Description
The participating health insurance funds are pursuing the goal of concluding rebate contracts with all suitable pharmaceutical companies in accordance with Section 130a (8) of the German Social Code, Book V for the active ingredient natalizumab (dosage form for subcutaneous injection). The contract is concluded within the framework of the open-house biologics procedure of the participating health insurance funds:Individual negotiations on contract content are not conducted; uniform conditions apply. The participating health insurers do not guarantee exclusivity to individual contract partners. The contract period is a maximum of 24 months beginning on 01.02.2023 (in deviation from this, the discount start date for hkk is 01.10.2023). The contract ends on 31.01.2025 at the latest, irrespective of the date on which the contract was concluded.In the event of patent expiry before 31.01.2025, the contract ends automatically at the end of the month of patent expiry.All further information can be found in the participation and contract documents.
Due to the existence of industrial property rights with regard to the active ingredient covered by the agreement, the participation and contract documents will only be made available to pharmaceutical companies that offer/market medicinal products containing the active ingredient covered by the agreement or that can credibly demonstrate to TK that they do so. A contract will be concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration of marketing authorization and company) and confirm this in electronic form in accordance with Section 126a of the German Civil Code (BGB).This announcement does not relate to the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The designation of the procedure "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. This and the use of the medium "TED" do not imply any submission to procurement law regulations, the application of which is not mandatory by law or procurement regulations.
- Opportunity closing date
- 31 January 2025
- Value of contract
- to be confirmed
About the buyer
- Address
- Techniker Krankenkasse Bramfelder Str. 140 Hamburg 22305 Germany
- Contact
- dzem@tk.de
Bid for tender
If your company meets the requirements of the tender, go to the website where the tender is hosted and submit your bid.
This website contains links to other websites that we do not control or maintain. We are not responsible for the content of these sites. We provide these links for your convenience only, and do not necessarily endorse their content.
Before entering into a contract you need to apply for any necessary export licences, which can include applications to trade in certain goods. You should also make your own enquiries and be satisfied by the accuracy of any information supplied to you.
This opportunity has been translated from its original language. You should check if you need to apply in the original language.